Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
NCT01635621 · UCB BIOSCIENCES GmbH · PHASE2 · withdrawn · last registry update 2012-10-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was withdrawn due to delay in timelines. There were no safety concerns regarding the study or the compound in the decision to withdraw the trial.” | – | Registry record, UCB BIOSCIENCES GmbH |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-05-17Phase 3 first posted: Janssen Research & Development, LLC, Sirukumab 100 mg + Sirukumab 50 mg (NCT01856309)
- 2013-02-20Also stopped (withdrawn): SWOG Cancer Research Network, CNTO 328 (NCT00311545)
- 2013-02-05Results posted on the registry: SWOG Cancer Research Network, CNTO 328 (NCT00433446)
- 2013-01-28Also stopped (withdrawn): Centocor, Inc., Placebo, Velcade and dexamethasone + Siltuximab, Velcade and dexamethasone (NCT01266811)
- 2012-09-21Phase 3 first posted: Janssen Pharmaceutical K.K., Sirukumab 100 mg + Sirukumab 50 mg (NCT01689532)
- 2012-05-28Phase 3 first posted: Janssen Research & Development, LLC, Placebo + Placebo (NCT01606761)
- 2012-05-23Phase 3 first posted: Janssen Research & Development, LLC, Placebo + Placebo (NCT01604343)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision